NCIt definition : A preparation of autologous activated T-lymphocytes that have been coated with a bispecific
antibody comprised of an anti-CD3 monoclonal antibody heteroconjugated to an anti-signaling
lymphocytic activation molecule family member 7 (SLAMF7; CD319; CRACC; CS-1) monoclonal
antibody, with potential immunomodulating and antineoplastic activities. Upon administration,
autologous anti-CD3/anti-SLAMF7 bispecific antibody-armed activated T-lymphocytes
target and bind to both CD3 expressed on T-cells and SLAMF7 expressed on tumor cells,
thereby cross-linking CD3-expressing T-cells and SLAMF7-expressing tumor cells. This
results in the activation of cytotoxic T-lymphocytes (CTLs) and selective cytotoxicity
towards SLAMF7-expressing tumor cells. In addition, cytokine and chemokine secretion
by the T-cells further activates the immune system, which leads to the recruitment
and activation of CTLs, and additional CTL-mediated tumor-specific cell lysis. SLAMF7
is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane
receptors that modulate the function of immune cells through immunoreceptor tyrosine-based
switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed
on certain malignant plasma cells and is minimally expressed on healthy immune cells.;